Scott L. Burrows
Insider Reports History
- Location
- Waltham, MA
- Signature
- /s/ Heidy King-Jones, as Attorney-in-Fact
- All insider transactions
- Transactions in reports broken out by “transaction date” reported in original SEC filing, see here for transactions aggregated across transaction date
Holdings reported by Scott L. Burrows:
| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Spyre Therapeutics, Inc. | Chief Financial Officer | Common Stock | 97,994 | $6,993,831 | $71.37 | 01 May 2026 | Direct |
| Arcutis Biotherapeutics, Inc. | Chief Financial Officer | Common Stock | 59,115 | $209,314 | $3.54 | 06 Mar 2023 | Direct |
| Spyre Therapeutics, Inc. | Chief Financial Officer | Stock Option (Right to Buy) | 382,357 | 01 May 2026 | Direct | ||
| Arcutis Biotherapeutics, Inc. | Chief Financial Officer | Stock Option (Right to Buy) | 55,800 | 02 Mar 2023 | Direct |
Insider Reports Filed by Scott L. Burrows
| Symbol | Company | Period | Transactions | Value $ | Form Type | Role | Filing Time |
|---|---|---|---|---|---|---|---|
| SYRE | Spyre Therapeutics, Inc. | 01 May 2026 | 3 | -$892,125 | 4 | Chief Financial Officer | 01 May 2026, 21:35 |
| SYRE | Spyre Therapeutics, Inc. | 01 Apr 2026 | 4 | -$370,076 | 4 | Chief Financial Officer | 03 Apr 2026, 21:29 |
| SYRE | Spyre Therapeutics, Inc. | 03 Mar 2026 | 4 | -$65,370 | 4 | Chief Financial Officer | 03 Mar 2026, 21:32 |
| SYRE | Spyre Therapeutics, Inc. | 09 Jan 2026 | 1 | $0 | 4 | Chief Financial Officer | 13 Jan 2026, 21:27 |
| SYRE | Spyre Therapeutics, Inc. | 02 Sep 2025 | 1 | -$299,639 | 4 | Chief Financial Officer | 03 Sep 2025, 18:53 |
| SYRE | Spyre Therapeutics, Inc. | 15 Jan 2025 | 1 | $0 | 4 | Chief Financial Officer | 17 Jan 2025, 16:36 |
| SYRE | Spyre Therapeutics, Inc. | 03 Sep 2024 | 1 | -$522,074 | 4 | Chief Financial Officer | 05 Sep 2024, 16:04 |
| SYRE | Spyre Therapeutics, Inc. | 01 Feb 2024 | 1 | $0 | 4 | Chief Financial Officer | 02 Feb 2024, 20:27 |
| SYRE | Spyre Therapeutics, Inc. | 22 Dec 2023 | 1 | $0 | 4 | Chief Financial Officer | 22 Dec 2023, 18:00 |
| SYRE | Aeglea BioTherapeutics, Inc. | 01 Sep 2023 | 1 | $0 | 4 | Chief Financial Officer | 05 Sep 2023, 16:10 |
| SYRE | Aeglea BioTherapeutics, Inc. | 01 Sep 2023 | 0 | $0 | 3 | Chief Financial Officer | 05 Sep 2023, 16:06 |
| ARQT | Arcutis Biotherapeutics, Inc. | 06 Mar 2023 | 1 | -$4,442 | 4 | Chief Financial Officer | 08 Mar 2023, 15:29 |
| ARQT | Arcutis Biotherapeutics, Inc. | 02 Mar 2023 | 2 | $0 | 4 | Chief Financial Officer | 06 Mar 2023, 17:58 |
| ARQT | Arcutis Biotherapeutics, Inc. | 28 Feb 2023 | 3 | -$29,421 | 4 | Chief Financial Officer | 02 Mar 2023, 18:05 |
| ARQT | Arcutis Biotherapeutics, Inc. | 16 Sep 2022 | 2 | +$8,403 | 4 | Chief Financial Officer | 20 Sep 2022, 16:37 |
| ARQT | Arcutis Biotherapeutics, Inc. | 03 Mar 2022 | 4 | -$5,104 | 4 | Chief Financial Officer | 07 Mar 2022, 19:49 |
| ARQT | Arcutis Biotherapeutics, Inc. | 01 Mar 2022 | 1 | -$7,456 | 4 | Chief Financial Officer | 03 Mar 2022, 15:17 |
| ARQT | Arcutis Biotherapeutics, Inc. | 30 Dec 2021 | 1 | $0 | 4 | Chief Financial Officer | 04 Jan 2022, 20:05 |
| ARQT | Arcutis Biotherapeutics, Inc. | 27 Dec 2021 | 1 | -$252,139 | 4 | Chief Financial Officer | 28 Dec 2021, 16:00 |